NASDAQ: IKT
Inhibikase Therapeutics Inc Stock Ownership - Who owns Inhibikase Therapeutics?

Insider buying vs selling

Have Inhibikase Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Sands Capital Life Sciences Pulse Fund II LP10% Owner2025-11-212,068,965$1.45
$3.00MBuy

1 of 1

IKT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when IKT insiders and whales buy or sell their stock.

IKT Shareholders

What type of owners hold Inhibikase Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Sands Capital Life Sciences Pulse Fund II LP9.86%13,018,965$26.43MInsider
Sands Capital Alternatives LLC9.86%13,018,965$26.43MInstitution
Soleus Capital Management LP8.24%10,875,000$22.08MInstitution
Fairmount Funds Management LLC6.53%8,625,000$17.51MInstitution
Adar1 Capital Management LLC6.11%8,063,949$16.37MInstitution
Trails Edge Capital Partners LP4.68%6,178,124$12.54MInstitution
Blackstone Inc4.50%5,938,276$12.05MInstitution
Siren LLC4.43%5,850,000$11.88MInstitution
Perceptive Advisors LLC4.11%5,421,568$11.01MInstitution
Commodore Capital LP4.09%5,397,488$10.96MInstitution

1 of 3

IKT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
IKT80.60%16.42%Net Buying
HELP60.30%0.00%
RNAC10.84%89.16%Net Buying
VYGR53.24%46.76%Net SellingNet Selling
FHTX71.32%14.46%

Inhibikase Therapeutics Stock Ownership FAQ

Who owns Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ: IKT) is owned by 80.60% institutional shareholders, 16.42% Inhibikase Therapeutics insiders, and 2.99% retail investors. Sands Capital Life Sciences Pulse Fund II LP is the largest individual Inhibikase Therapeutics shareholder, owning 13.02M shares representing 9.86% of the company. Sands Capital Life Sciences Pulse Fund II LP's Inhibikase Therapeutics shares are currently valued at $25.00M.

If you're new to stock investing, here's how to buy Inhibikase Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.